Apogee Therapeutics secures US$1.3B Blackstone deal for phase 3 eczema drug

USA—Apogee Therapeutics has secured up to US$1.3 billion in financing from Blackstone Life Sciences as it prepares to advance its anti–IL-13 antibody zumilokibart into Phase 3 trials for moderate-to-severe atopic dermatitis.

The agreement strengthens Apogee’s balance sheet as it approaches late-stage development and potential commercialization of its lead eczema therapy.

Structured funding with milestone-based access

Under the deal, Blackstone Life Sciences will provide up to US$800 million in exchange for low- to mid-single-digit tiered royalties on future zumilokibart sales for 15 years.

Apogee can access an initial US$100 million immediately, followed by US$100 million upon completion of Phase 3 enrollment, and a further US$200 million once pivotal data meets agreed criteria.

The remaining US$400 million will be disbursed only after U.S. FDA approval, according to the April 27 announcement.

The agreement also includes access to up to US$500 million in senior corporate debt, subject to mutual agreement between both parties, further expanding Apogee’s funding flexibility as it prepares for large-scale clinical and regulatory milestones.

Phase 2 results support Phase 3 progression

Apogee reported that mid-stage data for zumilokibart demonstrated strong efficacy in atopic dermatitis.

In a Phase 2 study, 65.9% of patients receiving the mid-dose achieved at least a 75% reduction in eczema severity at week 16, meeting the primary endpoint.

Analysts previously suggested the antibody could compete with Eli Lilly’s Ebglyss and Sanofi and Regeneron’s Dupixent based on cross-trial comparisons, although direct head-to-head data remain unavailable.

Leadership highlights non-dilutive capital strategy

Apogee CEO Michael Henderson said the Blackstone partnership provides non-dilutive capital that supports late-stage development while preserving shareholder value.

He added that the funding creates a pathway toward commercialization and strengthens the company’s ability to advance zumilokibart as a potential first-line therapy for moderate-to-severe atopic dermatitis.

Broader immunology pipeline expansion

Beyond dermatology, Apogee continues to develop zumilokibart across additional inflammatory and immune indications.

The company plans Phase 2 studies in eosinophilic esophagitis in the second half of 2026 and in asthma in the first half of 2027, reflecting a broader strategy to expand its immunology pipeline.

Blackstone reinforces biotech financing strategy

Blackstone Life Sciences Global Head Nicholas Galakatos described the transaction as part of the firm’s strategy to provide large-scale, non-dilutive financing to biotech companies advancing late-stage clinical programs.

He noted that similar investments recently supported Anagram Therapeutics, Teva, and Merck & Co. across oncology and gastrointestinal pipelines.

The company continues to position zumilokibart as a potential differentiated anti-IL-13 therapy in the competitive atopic dermatitis landscape, while investors closely monitor upcoming enrollment and data readouts.